---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060235"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:33:52.612039+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports Q3 net loss $21.2M; cash $215.7M; advances TYRA-300 and TYRA-200 trials

## Summary
- Q3 2023 net loss $21.2M vs $12.5M YoY; R&D expenses $19.3M (prior $10.9M).
- Cash and equivalents $215.7M as of Sept 30, 2023; funds operations for at least two years.
- SURF301 Phase 1/2 for TYRA-300 (FGFR3 inhibitor) dose escalation ongoing; preclinical achondroplasia data positive.
- TYRA-200 Phase 1 in FGFR2-altered cholangiocarcinoma on track to dose first patient by YE 2023.
- FDA granted TYRA-300 Orphan Drug Designation for achondroplasia in July 2023.

## SEC filing metadata
- accession: 0000950170-23-060235
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017023060235/0000950170-23-060235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017023060235/tyra-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060235
- JSON: https://secwatch.observer/filing/0000950170-23-060235.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060235.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported the quarter ended September 30, 2023 results: net income Third quarter 2023 net loss was $21.2 million.
  - Period: the quarter ended September 30, 2023
  - Net income: Third quarter 2023 net loss was $21.2 million
  - Result: reported results
  source text: Third quarter 2023 net loss was $21.2 million compared to $12.5 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017023060235/0000950170-23-060235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.